Influencing Factors of Treatment Response to Rituximab in Refractory Membranous Nephropathy
Rituximab demonstrates efficacy in treating refractory MN, with specific clinical and biochemical markers providing significant predictors of treatment success. The biomarker combination (serum albumin, creatinine, 24-hour urine protein, eGFR, PLA2R-Ab) offers exceptional predictive accuracy for treatment outcomes, providing clinicians with a practical tool to guide personalized treatment decisions and optimize resource allocation in refractory MN management.
Authors
- Lianzi Ma
- Jing Zheng (ORCID: https://orcid.org/0000-0002-7948-3388)
- Li Yang (ORCID: https://orcid.org/0000-0001-6285-3779)
Institutions
- Nanfang Hospital (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-08-01
- DOI
- https://doi.org/10.2147/dddt.s538971
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Southern Medical University
- Nanfang Hospital